DK1576112T3 - Cytokin-receptor zcytor17-multimerer - Google Patents

Cytokin-receptor zcytor17-multimerer

Info

Publication number: DK1576112T3
Authority: DK; Denmark
Prior art keywords: multimizer; amino acid; acid residues; cytokin; receptor zcytor17
Prior art date: 2002-01-18

Application number

DK03761891.5T

Other languages

English (en)

Inventor

Stacey R Dillon

Cindy A Sprecher

Zeren Gao

Joseph L Kuijper

Maria M Dasovich

Francis J Grant

Scott R Presnell

Theodore E Whitmore

Angela K Hammond

Julia E Novak

Jane A Gross

Original Assignee

Zymogenetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-18

Filing date

2003-01-21

Publication date

2012-06-25

2003-01-21 Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc

2012-06-25 Application granted granted Critical

2012-06-25 Publication of DK1576112T3 publication Critical patent/DK1576112T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK03761891.5T 2002-01-18 2003-01-21 Cytokin-receptor zcytor17-multimerer DK1576112T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US35032502P	2002-01-18	2002-01-18
US38910802P	2002-06-14	2002-06-14
US43536102P	2002-12-19	2002-12-19
PCT/US2003/001983 WO2004003140A2 (en)	2002-01-18	2003-01-21	Cytokine receptor zcytor17 multimers

Publications (1)

Publication Number	Publication Date
DK1576112T3 true DK1576112T3 (da)	2012-06-25

Family

ID=30003762

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03761891.5T DK1576112T3 (da)	2002-01-18	2003-01-21	Cytokin-receptor zcytor17-multimerer

Country Status (13)

Country	Link
US (24)	US7494804B2 (da)
EP (3)	EP2338910B1 (da)
JP (2)	JP4511349B2 (da)
AT (1)	ATE547430T1 (da)
AU (1)	AU2003280410B8 (da)
CA (1)	CA2473733C (da)
CY (1)	CY1112787T1 (da)
DK (1)	DK1576112T3 (da)
ES (2)	ES2546797T3 (da)
IL (3)	IL163067A (da)
PT (1)	PT1576112E (da)
SI (1)	SI1576112T1 (da)
WO (1)	WO2004003140A2 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE455852T1 (de) *	1999-06-02	2010-02-15	Chugai Pharmaceutical Co Ltd	Neues hämopoietin rezeptorprotein nr10
AU7445900A (en) *	1999-09-27	2001-04-30	Chugai Seiyaku Kabushiki Kaisha	Novel hemopoietin receptor protein, nr12
US20030096339A1 (en)	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
JP4511349B2 (ja) *	2002-01-18	2010-07-28	ザイモジェネティクス，インコーポレイティド	サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー
EP1476541B1 (en)	2002-01-18	2008-07-16	ZymoGenetics, Inc.	Cytokine (zcytor17 ligand)
US9738700B2 (en)	2002-01-18	2017-08-22	Zymogenetics Inc.	ZCYTOR17 heterodimeric cytokine receptor
JP2007068402A (ja) *	2003-12-26	2007-03-22	Bml Inc	免疫応答調節蛋白質
JP5179189B2 (ja) *	2004-11-03	2013-04-10	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	Ｔ細胞タンパク質及びそれをコードするヌクレオチド
ES2579758T3 (es) *	2005-01-28	2016-08-16	Zymogenetics, Inc.	Preparaciones homogéneas de IL-31
WO2006088855A1 (en) *	2005-02-14	2006-08-24	Zymogenetics, Inc.	Methods of treating skin disorders using an il-31ra antagonist
AU2012202218B2 (en) *	2005-02-14	2014-05-22	National Jewish Medical And Research Center	Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
EP1856150A2 (en) *	2005-02-14	2007-11-21	ZymoGenetics, Inc.	Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US20130216542A1 (en)	2005-05-06	2013-08-22	Zymogenetics, Inc.	Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en)	2005-05-06	2012-01-24	Zymogentics, Inc.	Variable region sequences of IL-31 monoclonal antibodies
JP5065253B2 (ja)	2005-05-06	2012-10-31	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−３１モノクローナル抗体とその使用法
US7972776B2 (en)	2005-11-15	2011-07-05	Oncohealth Corporation	Protein chips for HPV detection
MX2008008831A (es) *	2006-01-10	2009-03-04	Zymogenetics Inc	Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31.
DK2006381T3 (da) *	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til regulering af antistoffers blodfarmakokinetik
PE20080333A1 (es)	2006-06-08	2008-06-15	Chugai Pharmaceutical Co Ltd	Agentes para prevenir o tratar enfermedades inflamatorias
US7851144B2 (en)	2006-08-18	2010-12-14	The University Of Washington	Compositions and methods for detecting cancer
WO2008025032A1 (en) *	2006-08-25	2008-02-28	Zymogenetics, Inc.	Soluble il-27 receptor
DK2594586T3 (da)	2006-09-01	2014-11-17	Zymogenetics Inc	Monoklonale il-31-antistoffer og fremgangsmåder til anvendelse heraf
US8859218B2 (en)	2008-06-13	2014-10-14	Oncohealth Corp.	In situ detection of early stages and late stages HPV infection
US8968995B2 (en)	2008-11-12	2015-03-03	Oncohealth Corp.	Detection, screening, and diagnosis of HPV-associated cancers
AU2008204823A1 (en)	2007-01-10	2008-07-17	Zymogenetics, Inc	Methods of using IL-31 to treat airway hyper-responsiveness and asthma
DK2202245T3 (da) *	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til modificering af et antistofs isoelektriske punkt via aminosyresubstitution i cdr
ES2687808T3 (es)	2007-09-26	2018-10-29	Chugai Seiyaku Kabushiki Kaisha	Región constante de anticuerpo modificado
MX337081B (es) *	2007-12-05	2016-02-10	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-nr10 y su uso.
MY162546A (en)	2007-12-05	2017-06-15	Chugai Pharmaceutical Co Ltd	Therapeutic agent for pruritus
AU2008333131B2 (en)	2007-12-07	2013-10-24	Merck Serono S/A	Humanized antibody molecules specific for IL-31
PT2708559T (pt)	2008-04-11	2018-05-16	Chugai Pharmaceutical Co Ltd	Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
JO3382B1 (ar) *	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2010107110A1 (ja)	2009-03-19	2010-09-23	中外製薬株式会社	抗体定常領域改変体
TWI646193B (zh)	2009-03-19	2019-01-01	中外製藥股份有限公司	抗體恆定區域改變體
MX365235B (es)	2010-11-30	2019-05-28	Chugai Pharmaceutical Co Ltd	Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
SI2665486T1 (sl)	2011-01-18	2020-07-31	Bioniz, Llc	Sestavki za moduliranje aktivnosti gama-C-citokina
KR101882366B1 (ko)	2013-05-30	2018-07-30	키닉사 파마슈티컬스, 리미티드	온코스타틴 m 수용체 항원 결합 단백질
WO2015164107A1 (en)	2014-04-23	2015-10-29	Emory University	Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
WO2016167263A1 (ja)	2015-04-14	2016-10-20	中外製薬株式会社	Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
ES3036076T3 (en)	2015-04-14	2025-09-12	Chugai Pharmaceutical Co Ltd	Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
BR112018005503A2 (pt)	2015-09-23	2018-10-09	Koninklijke Philips N.V.	plataforma modular de oxímetro de pulso com módulos intercambiáveis para uso em um paciente e método para a operação de uma plataforma modular de oxímetro de pulso com módulos intercambiáveis para uso em um paciente
JP7165717B2 (ja)	2017-03-15	2022-11-04	パンディオン・オペレーションズ・インコーポレイテッド	標的免疫寛容
MX2019013517A (es)	2017-05-24	2020-08-17	Pandion Operations Inc	Inmunotolerancia dirigida.
US10322165B2 (en) *	2017-07-26	2019-06-18	Academia Sinica	TIFA antagonists and their use for treating diseases
CA3071376A1 (en)	2017-08-03	2019-02-07	Amgen Inc.	Interleukin-21 muteins and methods of treatment
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
AU2019207895A1 (en)	2018-01-12	2020-06-18	Amgen Inc.	Anti-PD-1 antibodies and methods of treatment
WO2020227019A1 (en)	2019-05-03	2020-11-12	Bioniz, Llc	Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
EP3972992A4 (en)	2019-05-20	2023-07-19	Pandion Operations, Inc.	MADCAM TARGETED IMMUNOTLERANCE
BR112022006590A2 (pt)	2019-11-20	2022-06-28	Chugai Pharmaceutical Co Ltd	Preparação contendo anticorpos
WO2021168079A1 (en)	2020-02-21	2021-08-26	Pandion Operations, Inc.	Tissue targeted immunotolerance with a cd39 effector
CA3186973A1 (en) *	2020-06-24	2021-12-30	Bioniz, Llc	Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders
JP6799831B1 (ja)	2020-09-01	2020-12-16	中外製薬株式会社	Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK368882A (da)	1981-08-25	1983-02-26	Alan John Kingsman	Expessions vektorer
US4579821A (en)	1981-11-23	1986-04-01	University Patents, Inc.	Control of DNA sequence transcription
US4656134A (en)	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
US4486533A (en)	1982-09-02	1984-12-04	St. Louis University	Filamentous fungi functional replicating extrachromosomal element
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en)	1985-06-26	1990-12-11	Amgen	Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4603044A (en)	1983-01-06	1986-07-29	Technology Unlimited, Inc.	Hepatocyte Directed Vesicle delivery system
US4713339A (en)	1983-01-19	1987-12-15	Genentech, Inc.	Polycistronic expression vector construction
US5139936A (en)	1983-02-28	1992-08-18	Collaborative Research, Inc.	Use of the GAL1 yeast promoter
US4661454A (en)	1983-02-28	1987-04-28	Collaborative Research, Inc.	GAL1 yeast promoter linked to non galactokinase gene
US4650764A (en)	1983-04-12	1987-03-17	Wisconsin Alumni Research Foundation	Helper cell
US4870008A (en)	1983-08-12	1989-09-26	Chiron Corporation	Secretory expression in eukaryotes
US4931373A (en)	1984-05-25	1990-06-05	Zymogenetics, Inc.	Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en)	1985-02-25	1988-08-23	Zymogenetics Inc.	Expression of biologically active PDGF analogs in eucaryotic cells
EP0184576B1 (en)	1984-12-06	1990-06-27	Fina Research S.A.	Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
US4882279A (en)	1985-10-25	1989-11-21	Phillips Petroleum Company	Site selective genomic modification of yeast of the genus pichia
US4935349A (en)	1986-01-17	1990-06-19	Zymogenetics, Inc.	Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en)	1986-05-15	1986-06-25	Holland I B	Polypeptide
US4980289A (en)	1987-04-27	1990-12-25	Wisconsin Alumni Research Foundation	Promoter deficient retroviral vector
US5063154A (en)	1987-06-24	1991-11-05	Whitehead Institute For Biomedical Research	Pheromone - inducible yeast promoter
US5567584A (en)	1988-01-22	1996-10-22	Zymogenetics, Inc.	Methods of using biologically active dimerized polypeptide fusions to detect PDGF
ATE140963T1 (de)	1988-01-22	1996-08-15	Zymogenetics Inc	Verfahren zur herstellung von sekretierten rezeptoranalogen
US4956288A (en)	1988-04-22	1990-09-11	Biogen, Inc.	Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en)	1988-08-05	1991-08-06	Zymogenetics, Inc.	BAR1 secretion signal
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5162228A (en)	1988-12-28	1992-11-10	Takeda Chemical Industries, Ltd.	Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5124263A (en)	1989-01-12	1992-06-23	Wisconsin Alumni Research Foundation	Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5162222A (en)	1989-07-07	1992-11-10	Guarino Linda A	Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en)	1990-09-28	1992-08-18	Ixsys Inc	Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2097291A1 (en)	1990-12-13	1992-06-14	David P. Gearing	Leukemia inhibitory factor receptors
JP3202999B2 (ja)	1991-01-31	2001-08-27	協和醗酵工業株式会社	肝移行性リポソーム製剤
US5298418A (en)	1991-09-16	1994-03-29	Boyce Thompson Institute For Plant Research, Inc.	Cell line isolated from larval midgut tissue of Trichoplusia ni
EP0749319A1 (en)	1992-09-14	1996-12-27	Pfizer Inc.	Immortalized cells and uses therefor
JPH09501055A (ja)	1993-07-30	1997-02-04	ユニバーシティオブメディシンアンドデンティストリーオブニュージャージー	初代リンパ球への効率的遺伝子転移
EP0745132A1 (en)	1994-02-14	1996-12-04	ZymoGenetics, Inc.	Method for preparing orphan receptor ligands
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5783672A (en) *	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
CN1075387C (zh) *	1994-12-29	2001-11-28	中外制药株式会社	含有il－6拮抗剂的抗肿瘤剂的作用增强剂
US6074849A (en) *	1995-07-19	2000-06-13	Genetics Institute, Inc.	Polynucleotides encoding human CTLA-8 related proteins
WO1997017451A2 (en)	1995-11-09	1997-05-15	Zymogenetics, Inc.	Production of gad65 in methylotrophic yeast
US5792850A (en) *	1996-05-23	1998-08-11	Zymogenetics, Inc.	Hematopoietic cytokine receptor
JP2002514049A (ja)	1996-07-17	2002-05-14	ザイモジェネティクス，インコーポレイティド	ピヒア・メタノリカの栄養要求性突然変異体の製造
AU718510B2 (en)	1996-07-17	2000-04-13	Zymogenetics Inc.	Transformation of pichia methanolica
WO2002000690A2 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE69738539T2 (de)	1996-12-03	2009-03-26	Amgen Fremont Inc.	Vollkommen humane Antikörper die EGFR binden
GB9819420D0 (en)	1998-09-07	1998-10-28	Glaxo Group Ltd	Novel receptor
ES2322791T5 (es)	1999-06-01	2013-11-29	Merck Sharp & Dohme Corp.	Proteínas receptoras de mamíferos; reactivos y métodos relacionados
ATE455852T1 (de) *	1999-06-02	2010-02-15	Chugai Pharmaceutical Co Ltd	Neues hämopoietin rezeptorprotein nr10
AU1095001A (en) *	1999-10-20	2001-04-30	Genentech Inc.	Type i cytokine receptor tccr
AU6531101A (en) *	2000-06-02	2001-12-17	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004501628A (ja)	2000-06-26	2004-01-22	ザイモジェネティクス，インコーポレイティド	サイトカイン受容体ｚｃｙｔｏｒ１７
US20030096339A1 (en) *	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
JP2005507632A (ja)	2000-10-06	2005-03-24	イミュネックス・コーポレーション	ヘマトポエチン受容体、ｈｐｒ１およびｈｐｒ２
WO2002077230A1 (fr)	2001-03-26	2002-10-03	Chugai Seiyaku Kabushiki Kaisha	Variants d'epissage nr10
EP1476541B1 (en)	2002-01-18	2008-07-16	ZymoGenetics, Inc.	Cytokine (zcytor17 ligand)
JP4511349B2 (ja) *	2002-01-18	2010-07-28	ザイモジェネティクス，インコーポレイティド	サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー
US7303896B2 (en) *	2002-02-25	2007-12-04	Genentech, Inc.	Nucleic acid encoding novel type-1 cytokine receptor GLM-R
US7552497B2 (en) *	2002-03-26	2009-06-30	Colgate-Palmolive Company	Powered toothbrush with rotating sections
WO2006088855A1 (en)	2005-02-14	2006-08-24	Zymogenetics, Inc.	Methods of treating skin disorders using an il-31ra antagonist

2003
- 2003-01-21 JP JP2004517500A patent/JP4511349B2/ja not_active Expired - Fee Related
- 2003-01-21 AU AU2003280410A patent/AU2003280410B8/en not_active Ceased
- 2003-01-21 CA CA2473733A patent/CA2473733C/en not_active Expired - Fee Related
- 2003-01-21 SI SI200332153T patent/SI1576112T1/sl unknown
- 2003-01-21 ES ES11151759.5T patent/ES2546797T3/es not_active Expired - Lifetime
- 2003-01-21 ES ES03761891T patent/ES2382800T3/es not_active Expired - Lifetime
- 2003-01-21 EP EP11151759.5A patent/EP2338910B1/en not_active Expired - Lifetime
- 2003-01-21 DK DK03761891.5T patent/DK1576112T3/da active
- 2003-01-21 AT AT03761891T patent/ATE547430T1/de active
- 2003-01-21 EP EP14185668.2A patent/EP2840089A1/en not_active Withdrawn
- 2003-01-21 WO PCT/US2003/001983 patent/WO2004003140A2/en not_active Ceased
- 2003-01-21 US US10/351,157 patent/US7494804B2/en not_active Expired - Fee Related
- 2003-01-21 EP EP03761891A patent/EP1576112B1/en not_active Expired - Lifetime
- 2003-01-21 PT PT03761891T patent/PT1576112E/pt unknown
2004
- 2004-07-15 IL IL163067A patent/IL163067A/en not_active IP Right Cessation
- 2004-07-15 IL IL226637A patent/IL226637A/en not_active IP Right Cessation
2006
- 2006-10-25 US US11/552,647 patent/US20070048832A1/en not_active Abandoned
- 2006-10-25 US US11/552,688 patent/US20070048833A1/en not_active Abandoned
- 2006-10-25 US US11/552,637 patent/US20070048831A1/en not_active Abandoned
- 2006-10-25 US US11/552,710 patent/US20070048834A1/en not_active Abandoned
- 2006-10-25 US US11/552,721 patent/US20070048835A1/en not_active Abandoned
- 2006-10-25 US US11/552,653 patent/US20070049530A1/en not_active Abandoned
- 2006-10-26 US US11/553,241 patent/US20070140964A1/en not_active Abandoned
- 2006-10-26 US US11/553,219 patent/US20070140963A1/en not_active Abandoned
- 2006-10-27 US US11/553,821 patent/US20070048222A1/en not_active Abandoned
- 2006-10-27 US US11/553,835 patent/US20070048223A1/en not_active Abandoned
2009
- 2009-04-28 US US12/431,623 patent/US20100266597A1/en not_active Abandoned
- 2009-04-29 US US12/432,286 patent/US20100266499A1/en not_active Abandoned
- 2009-06-12 US US12/484,019 patent/US20090274694A1/en not_active Abandoned
- 2009-08-21 US US12/545,770 patent/US20100055101A1/en not_active Abandoned
- 2009-10-27 JP JP2009246276A patent/JP2010043120A/ja active Pending
2011
- 2011-04-13 US US13/085,645 patent/US20110318354A1/en not_active Abandoned
2012
- 2012-02-27 US US13/405,916 patent/US20120264168A1/en not_active Abandoned
- 2012-05-25 CY CY20121100477T patent/CY1112787T1/el unknown
2013
- 2013-01-14 US US13/741,036 patent/US8647866B2/en not_active Expired - Fee Related
- 2013-05-29 IL IL226637A patent/IL226637A0/en unknown
- 2013-12-23 US US14/138,199 patent/US9212213B2/en not_active Expired - Fee Related
2015
- 2015-09-17 US US14/856,588 patent/US20160002340A1/en not_active Abandoned
2017
- 2017-03-31 US US15/476,006 patent/US20170204190A1/en not_active Abandoned
- 2017-07-12 US US15/648,203 patent/US10227415B2/en not_active Expired - Fee Related
- 2017-09-11 US US15/701,214 patent/US20170369580A1/en not_active Abandoned
2018
- 2018-08-10 US US16/100,485 patent/US20180346584A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100055101A1 (en)	2010-03-04
IL226637A (en)	2017-11-30
CY1112787T1 (el)	2016-02-10
CA2473733A1 (en)	2004-01-08
US20070048832A1 (en)	2007-03-01
EP2338910B1 (en)	2015-07-08
AU2003280410B8 (en)	2009-04-23
WO2004003140A3 (en)	2005-09-01
US20140141485A1 (en)	2014-05-22
US8647866B2 (en)	2014-02-11
US20160002340A1 (en)	2016-01-07
US20100266499A1 (en)	2010-10-21
US20110318354A1 (en)	2011-12-29
US20070140963A1 (en)	2007-06-21
US20070048835A1 (en)	2007-03-01
IL163067A (en)	2013-07-31
PT1576112E (pt)	2012-05-25
US7494804B2 (en)	2009-02-24
AU2003280410A1 (en)	2004-01-19
US20070048833A1 (en)	2007-03-01
US20170320931A1 (en)	2017-11-09
SI1576112T1 (sl)	2012-10-30
JP2010043120A (ja)	2010-02-25
JP4511349B2 (ja)	2010-07-28
US20070048834A1 (en)	2007-03-01
EP2338910A1 (en)	2011-06-29
EP1576112A2 (en)	2005-09-21
US20070049530A1 (en)	2007-03-01
ATE547430T1 (de)	2012-03-15
US20070048223A1 (en)	2007-03-01
US20070048831A1 (en)	2007-03-01
US20030215838A1 (en)	2003-11-20
JP2006500919A (ja)	2006-01-12
US10227415B2 (en)	2019-03-12
AU2003280410B2 (en)	2009-04-02
EP1576112B1 (en)	2012-02-29
EP1576112A4 (en)	2007-09-05
ES2382800T3 (es)	2012-06-13
CA2473733C (en)	2014-09-09
US20120264168A1 (en)	2012-10-18
IL226637A0 (en)	2013-06-27
US20170204190A1 (en)	2017-07-20
US20180346584A1 (en)	2018-12-06
ES2546797T3 (es)	2015-09-28
EP2840089A1 (en)	2015-02-25
US20100266597A1 (en)	2010-10-21
US20170369580A1 (en)	2017-12-28
US9212213B2 (en)	2015-12-15
WO2004003140A2 (en)	2004-01-08
US20070140964A1 (en)	2007-06-21
US20090274694A1 (en)	2009-11-05
US20070048222A1 (en)	2007-03-01
US20130143265A1 (en)	2013-06-06

Publication	Publication Date	Title
DK1576112T3 (da)	2012-06-25	Cytokin-receptor zcytor17-multimerer
DK1476541T3 (da)	2008-11-03	Cytokin (zcytor17-ligand)
NO2020016I1 (no)	2020-06-12	efmoroktokog alfa - forlenget SPC
CY1109725T1 (el)	2014-08-13	Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
IL195338A (en)	2015-08-31	An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DK1642973T3 (da)	2009-11-02	Terapeutisk anvendelser af BR43X2-oplöselige receptorer
UY28641A1 (es)	2005-06-30	Anticuerpos
ATE396264T1 (de)	2008-06-15	Zytokinrezeptoruntereinheit-proteine aus säugetieren, damit zusammenhängende reagenzien und methoden
ATE417275T1 (de)	2008-12-15	Puffern zur stabilizierung von hcv antigenen
DE69918946D1 (de)	2004-09-02	Rezeptoren für il-18
DK1699822T3 (da)	2008-08-04	IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
EP1589106A4 (en)	2006-06-07	ADIPONEKTIN RECEPTOR AND GENERATING ENCODER
ATE446104T1 (de)	2009-11-15	Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
NZ606260A (en)	2014-10-31	Novel polypeptides involved in immune response